ether has been researched along with Diabetes Mellitus, Type 2 in 4 studies
Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.
ether : An organooxygen compound with formula ROR, where R is not hydrogen.
diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Taken together, the observed lipidome changes in obesity and T2D will facilitate the identification of T2D patient subgroups and represent an important step towards personalized medicine in diabetes." | 4.02 | Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients. ( Brown, SA; Brulhart-Meynet, MC; Chanon, S; David, FPA; Dermitzakis, ET; Dibner, C; Durand, C; Golay, A; Gosselin, P; Guessous, I; Hannich, JT; Harayama, T; Jornayvaz, FR; Lefai, E; Loizides-Mangold, U; Pataky, Z; Paz Montoya, J; Philippe, J; Riezman, H; Robert, M; Saini, C; Sinturel, F; Vandereycken, B, 2021) |
| "Salicin ether treatment of the adipocytes effectively suppressed rosiglitazone induced expression of FAS, C/EBPα, aP2, and HMG-CoA genes." | 1.72 | Preventive effect of salicin ether against type-2 diabetes mellitus through targeting PPARγ-regulated gene expression. ( Xiang, G; Yue, L; Zhang, J; Zhu, G, 2022) |
| "These "overnutrition" diets also promote the accumulation of a variety of harmful lipids in the heart and other peripheral organs, known as lipotoxicity." | 1.72 | Reducing ether lipids improves Drosophila overnutrition-associated pathophysiology phenotypes via a switch from lipid storage to beta-oxidation. ( Alvi, A; Finsel, P; Musselman, LP; O'Toole, A; Santoro, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, G | 1 |
| Zhang, J | 1 |
| Yue, L | 1 |
| Xiang, G | 1 |
| Santoro, C | 1 |
| O'Toole, A | 1 |
| Finsel, P | 1 |
| Alvi, A | 1 |
| Musselman, LP | 1 |
| Hannich, JT | 1 |
| Loizides-Mangold, U | 1 |
| Sinturel, F | 1 |
| Harayama, T | 1 |
| Vandereycken, B | 1 |
| Saini, C | 1 |
| Gosselin, P | 1 |
| Brulhart-Meynet, MC | 1 |
| Robert, M | 1 |
| Chanon, S | 1 |
| Durand, C | 1 |
| Paz Montoya, J | 1 |
| David, FPA | 1 |
| Guessous, I | 1 |
| Pataky, Z | 1 |
| Golay, A | 1 |
| Jornayvaz, FR | 1 |
| Philippe, J | 1 |
| Dermitzakis, ET | 1 |
| Brown, SA | 1 |
| Lefai, E | 1 |
| Riezman, H | 1 |
| Dibner, C | 1 |
| Sen, P | 1 |
| Hyötyläinen, T | 1 |
| Orešič, M | 1 |
4 other studies available for ether and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Preventive effect of salicin ether against type-2 diabetes mellitus through targeting PPARγ-regulated gene expression.
Topics: AMP-Activated Protein Kinases; Benzyl Alcohols; CCAAT-Enhancer-Binding Protein-alpha; Cell Different | 2022 |
Reducing ether lipids improves Drosophila overnutrition-associated pathophysiology phenotypes via a switch from lipid storage to beta-oxidation.
Topics: Animals; Diabetes Mellitus, Type 2; Drosophila; Ether; Lipids; Metabolic Diseases; Obesity; Overnutr | 2022 |
Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Ether; Humans; Lipids; Mice; Obesity; Sphingolip | 2021 |
1-Deoxyceramides - Key players in lipotoxicity and progression to type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Ether; Humans; Lipids; Obesity; Sphingolipids | 2021 |